DeepCovalent’s OS3D™ delivers single-step, seed-free de novo small-molecule generation, enabling unbiased access to novel chemical space beyond incremental analog design. Its multimodal, multi-objective architecture conditions generation simultaneously on target biology, efficacy signals, ADMET profiles, and medicinal chemistry constraints—producing synthesis-ready candidates with early translational relevance. By unifying ideation, design, and in-silico validation into a single forward pass, it generates optimized and in-silico validated molecules faster, leaner, and beyond known chemistry.
One-Step-Denovo™ Drug Discovery (OS3D™)
Reverse trial-and-error approach.
Manual and sequential iteration across chemistry, biology, and ADMET.
Traditional Wrokflow is Slow and Costly
GenAI-driven design enables one-step forward drug discovery.
Rapid generation and evaluation of small molecule candidates in-silico.
OS3D™: Ideation to Molecule in 3 Weeks
Incomplete modeling of protein–ligand context and clinical constraints.
Optimization constrained to known chemical space.
Why 90% of Drugs Fail in Clinical Trials
Unified multimodal and multi-objective modeling of protein–ligand systems.
Integrates biology, bioactivity, and rich ADMET context.
Unbiased access to previously unknown chemical space.